Vivani

Vivani Medical can confirm the successful administration of the first GLP-1 (exenatide) implant in the LIBERATE-1? clinical trial. ? This marks a significant step in advancing chronic weight management solutions, with top-line results expected in mid-2025. ? Read more here: https://lnkd.in/eC7MvuhA. ? #VivaniMedical #ClinicalTrial #HealthcareInnovation #GLP1 #WeightManagement

Vivani Medical has announced the intent to spin-off Cortigent, Inc., our neurostimulation division. This strategic move will allow both companies to focus on their core strengths. ? Cortigent will advance its brain implant devices, while Vivani will develop miniature, long-acting drug implants for chronic weight management and type 2 diabetes. ? This spin-off is expected to unlock significant value for our shareholders and enhance our ability to deliver transformative therapies. ? Read more here: https://lnkd.in/exvdCPdX. ? #VivaniMedical #Cortigent #Neurostimulation #HealthcareInnovation #Biopharmaceuticals #MedicalDevices

Vivani Medical has announced the intent to spin-off Cortigent, Inc., our neurostimulation division. This strategic move will allow both companies to focus on their core strengths. ? Cortigent will advance its brain implant devices, while Vivani will develop miniature, long-acting drug implants for chronic weight management and type 2 diabetes. ? This spin-off is expected to unlock significant value for our shareholders and enhance our ability to deliver transformative therapies. ? Read more here: https://lnkd.in/exvdCPdX. ? #VivaniMedical #Cortigent #Neurostimulation #HealthcareInnovation #Biopharmaceuticals #MedicalDevices

Vivani Medical’s team consists of successful industry veterans who position us for success in our near- and short-term objectives. Learn more about Vivani: https://vivani.com/ #VivaniMedical Adam Mendelsohn

Viavni CEO Adam Mendelsohn contributed to an insightful piece to MedCity News on the critical role of medication delivery in addressing non-adherence. ? Dr. Mendelsohn explores the challenges and innovative solutions in medication adherence, particularly for chronic conditions like diabetes and obesity. ? Read the article here: https://lnkd.in/gKXUahbP. ? #HealthcareInnovation #MedicationAdherence #ChronicDiseaseManagement #VivaniMedical #MedCityNews

We’re committed to addressing the global obesity crisis. Did you know that by 2035, over 1 billion people worldwide are projected to be living with obesity? This alarming statistic underscores the urgent need for comprehensive strategies to combat this epidemic. ? At Vivani Medical, we are taking innovative steps to combat obesity through our NanoPortal? implant technology. Our lead program, NPM-115, utilizes a miniature, six-month, subdermal GLP-1 (exenatide) implant designed for chronic weight management in obese or overweight individuals. This implant aims to provide steady doses of medication, addressing medication non-adherence and improving treatment outcomes. ? Learn more about #WorldObesityDay here: https://lnkd.in/eS38U52. World Obesity Federation #WorldObesityDay #HealthAwareness #VivaniMedical #GlobalHealth

This National Cat Health Month, we're excited to highlight our pipeline asset developed in partnership with OKAVA: OKV-119. This innovative treatment candidate addresses two major health concerns in cats—obesity and diabetes. ? With 61% of cats in the U.S. considered obese by their veterinarians, this concern is widespread and has a direct impact on their mortality. ? Learn more about Vivani and OKV-119: https://lnkd.in/eTfjt9-R. #VivaniMedical #NationalCatHealthMonth #AnimalHealth ? Adam Mendelsohn

Vivani CEO Adam Mendelsohn recently sat down for an insightful interview with The Educated Patient, during which he discussed the latest innovations in GLP-1 therapy and how Vivani is pioneering advancements in the field. ? See the interview here: https://lnkd.in/dP2i-CPT. ? #MedicalInnovation #GLP1Therapy #VivaniMedical #Healthcare #PatientCare

Obesity is a major risk factor for heart disease, the leading cause of death in the U.S. Vivani is committed to developing innovative treatments that address this critical public health issue. Through advances in GLP-1 delivery, we aim to help patients manage obesity and reduce their cardiovascular disease burden. This American Heart Month, we renew our focus on improving cardiometabolic health for all. #AmereicanHeartMonth

Vivani CEO Adam Mendelsohn sat down with Bradley Bostic's Boombostic Health Podcast while at last month’s JP Morgan Healthcare Conference. The two discussed Vivani's implant technology, which is designed to improve medication adherence and long-term health outcomes, and is currently being investigated in combating obesity and diabetes with implantable GLP-1 medications. #JPM2025 #GLP1 #obesity #diabetes #jpmorganhealthcareconference